Recent Updates
Recently added Catalysts
ABBV

Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended

Key Takeaway: Guidance Including the Impact of Acquired IPR D and Milestones Expense (in millions, except per share data) Quarter Ended September 30, 2022 Full-Year Ended December 31, 2022 Acquired IPR D and Milestones Expense Adjusted Diluted EPS Range Acquired IPR D and Milestones Expen

Full Press Release Details

Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data) Quarter Ended September 30, 2022 Full-Year Ended December 31, 2022
Acquired IPR D and Milestones Expense Adjusted Diluted EPS Range Acquired IPR D and Milestones Expense Adjusted Diluted EPS Range
Low High Low High
Previously announced guidance excluding Q3 2022 acquired IPR D and milestones expense $ - $ 3.55 $ 3.59 $ 414 $ 13.78 $ 13.98
Q3 2022 acquired IPR D and milestones expense 40 (0.02) (0.02) 40 (0.02) (0.02)
Guidance including Q3 2022 acquired IPR D and milestones expense a $ 40 $ 3.53 $ 3.57 $ 454 $ 13.76 $ 13.96
a The Company's 2022 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the third quarter of 2022, as both cannot be reliably forecasted.
Last updated: Sep 30, 2022